|
|
||||||||



Departments of
*
Microbiology, Immunology, and Molecular Genetics and
Medicine, School of Medicine, University of California, Los Angeles, CA 90024;
Department of Infectious Diseases, Quest Diagnostics, Inc., San Juan Capistrano, CA 92690; and
§
Hybridoma Facility, Department of Microbiology, Pathology, and Parasitology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
We have reported previously the development of a procedure to isolate the outer membrane from T.p. and have identified a limited set of outer membrane proteins including those of molecular mass 17, 28, 31, 45, and 65 kDa (6). The 17- and 45-kDa proteins are lipoproteins (7, 8) and are primarily associated in greater amounts with the T.p. inner membrane protoplasmic cylinder complex (6, 9). These outer membrane lipoproteins are not membrane-spanning and are apparently not surface exposed; rather, they are anchored to the inner leaflet of the outer membrane (6). By comparison, the 28- and 31-kDa proteins are markedly enriched in outer membrane preparations and have been shown to be hydrophobic (6, 10, 11). The 31-kDa protein is also not found with the protoplasmic cylinder complex following gentle detergent treatment of T.p., which completely solubilizes the outer membrane (10). Both purified native and an Escherichia coli recombinant outer membrane form of the 31-kDa protein, designated Tromp1, exhibit porin activity (10, 12). The 28-kDa protein, designated Tromp2, has also been expressed in E. coli, where it targets exclusively to the E. coli outer membrane (11). Tromp1 and Tromp2 are antigenic, using infection-derived immune serum; however, both of these proteins are weakly immunogenic compared with the lipoproteins.
There is evidence that the protective immunity acquired during latent syphilitic infection in humans and experimental animals results from specific Ab in immune serum (13). The development and persistence of acquired immunity in experimental rabbit syphilis has been shown to correlate with the presence of high-titer (range of 1:161:128) complement-dependent treponemicidal Ab (14). Humans exhibiting latent infection have also been shown to have similar levels of high-titer (range of 1:81:128) serum treponemicidal activity (13). Of particular significance is the demonstration that rabbits, hamsters, and guinea pigs can be passively protected from challenge infection using serum from immune donors (15, 16, 17, 18, 19, 20, 21, 22). These observations have provided compelling evidence that Ab plays a key role in the protective immunity that develops during syphilitic infection. However, the specific T.p. target(s) of high-titer treponemicidal Ab and of protective immunity has not been identified. In addition, immunizations with either killed whole organisms, fractionated organisms, or recombinant proteins have failed to elicit serum treponemicidal activity comparable with that of immune serum. Because the outer membrane contains the likely surface targets for killing Ab, we immunized a mouse with the maximum amount of purified T.p. outer membrane that can be reasonably obtained in an effort to elicit high-titer complement-dependent treponemicidal Ab and identify the target molecules of this activity.
| Materials and Methods |
|---|
|
|
|---|
For immunization and immunoblot analysis,
78 x
1010 T.p. equivalents of purified outer membrane
were prepared as described previously (6). Because the
recovery of purified outer membrane using this procedure is <5%
efficient, outer membrane isolations were performed on
1.4 x
1012 organisms; these isolations were
accomplished over several months by extracting organisms from seven
groups of 10 rabbits infected intratesticularly with a total of 4
x 107 T.p. (a total of 70 rabbits). In addition,
the previous use of octyl-decyl rhodamine chloride to label and
visualize membrane was not used in these isolations, resulting in no
difference in the visualized membrane banding position following outer
membrane purification through sucrose density gradients or in the
protein composition of the purified membrane (data not shown).
Mouse immunization with T.p. outer membrane
For the mouse immunization with purified T.p. outer membrane
vesicles (OMV), a 12-wk-old female BALB/c mouse (Charles River,
Raleigh, NC) was injected s.c. in two sites with OMV derived from
1 x 1011 T.p., containing
1050 ng of
each outer membrane protein, mixed 1:1 with titermax adjuvant (CytRx,
Norcross, GA). At 2 and 5 mo, the mouse was boosted with a similar
amount of outer membrane material by direct intrasplenic injection
while under anesthesia (2.5 mg/mouse of ketamine HCl (Fort Dodge
Laboratories, Fort Dodge, IA) and 0.5 mg/mouse of Rompun (Miles,
Shawnee Mission, KS). A final i.v. boost with a similar amount of OMV
material was given at 8 mo. After 5 days, the mouse was exsanguinated
via cardiac puncture with the blood processed into
400 µl of
serum. Nonautologous control serum came from a syngeneic littermate.
Serum was also acquired from syphilitic rabbits immune to challenge
(immune rabbit serum (IRS)); rabbits were infected for 6 mo following
intratesticular injection with 4 x 107 T.p.
One- and two-dimensional SDS-PAGE and immunoblotting
T.p. Ag and purified T.p. outer membrane were prepared for two-dimensional immunoblot analysis as described previously (6). Briefly, 1 x 109 Ficoll purified T.p. or outer membrane from 5 x 1010 whole organism equivalents were solubilized for 1 h at room temperature in sample buffer containing 9 M urea, 2% Nonidet P-40, and 2% carrier ampholytes at a pH of 9.5. Isoelectric focusing was conducted for 16 h at a constant voltage of 600 V in polyacrylamide tube gels containing 2% (pH 57) and 0.8% (pH 310) Ampholines (Bio-Rad, Richmond, CA), 2% Nonidet P-40, and 9 M urea. The second dimension consisted of standard SDS-PAGE as described previously (6). After electrophoresis, gels were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA) (23) and stained with 1% amido black.
Recombinant 31-kDa Tromp1 was expressed and purified by fast performance liquid chromatography (Pharmacia LKB Biotechnology, Uppsala, Sweden) as described previously (12). Approximately 5 µg of purified recombinant Tromp1 was electrophoresed by standard SDS-PAGE and transferred to polyvinylidene difluoride membranes for immunoblot analysis as described previously (12).
For immunoblot analysis, the mouse anti-T.p. OMV serum and IRS were each diluted 1/1000 in PBS containing 5% nonfat dry milk (Carnation, Los Angeles, CA) and 0.1% Tween-20 (Sigma, St. Louis, MO) (MT-PBS). The diluted sera were incubated on blots for 1 h; Ab-Ag binding was detected using an enhanced chemiluminescence system (Amersham, Little Chalfont, U.K.). Blots were incubated for 1 h in either anti-mouse or anti-rabbit Ig conjugated to HRP (Amersham) diluted 1/2500 in MT-PBS. Blots were subsequently washed in PBS containing 0.1% Tween-20, incubated for 1 min in the enhanced chemiluminescence developing reagents (Amersham), and chemilumigraphed with Kodak X-AR5 film.
T.p. immobilization (TPI) testing
To assay for serum complement-dependent killing Ab against T.p., the TPI test was used as described previously (24). Heat-inactivated (56°C/30 min) IRS and heat-inactivated mouse anti-T.p. OMV serum were tested quantitatively using 2-fold serial dilutions in heat-inactivated normal rabbit serum (NRS) with a nonreactive venereal disease research laboratory (VDRL) test (24). Samples (50 µl) of 2-fold diluted test serum were added to a final volume of 550 µl (final test serum dilution for each tube is 1/11) containing 250 µl of Nelsons medium (24, 25), 200 µl of fresh guinea pig serum, both heat-inactivated and unheated as a source of active complement, and 50 µl of a T.p. suspension containing 5 x 107 organisms/ml. The mixtures were incubated in an atmosphere of 95% N2 to 5% CO2 for 16 h at 34°C, at which time samples were observed by darkfield microscopy for the presence of motile vs nonmotile treponemes. Percent motility was determined by randomly counting 25 organisms. Organisms immobilized under similar conditions have been shown to be killed based upon virulence testing using intradermal injection of rabbits (14). The 100% and 50% endpoint killing titers were determined based on the final serum dilutions capable of immobilizing 100% and 50% of the treponemes counted, respectively.
Absorption of anti-OMV serum
To remove Ab from the mouse anti-OMV serum directed against subsurface T.p. lipoproteins, the serum was absorbed three times with T.p. protoplasmic cylinders, devoid of outer membrane, which were prepared as follows. Approximately 2 x 1011 T.p. were extracted from 10 intratesticularly infected rabbits in 400 ml of PBS (pH 7.2) containing 6 U/ml of sodium heparin. The suspension was centrifuged two times at 400 x g to remove gross tissue debris and subsequently at 20,000 x g for 20 min to pellet the treponemes. The treponemal pellet was resuspended in 18 ml of PBS, to which 2 ml of 10% Triton X-100 was added (1% final Triton X-100 concentration). The suspension was then incubated for 4 h at 4°C to solubilize the outer membrane. The suspension was divided into three equal volumes and centrifuged at 10,000 x g for 20 min. Treponemal pellets were washed once in 10 ml of PBS and subsequently recentrifuged as described previously. The resulting protoplasmic cylinders were shown to be free of outer membrane by the failure to detect Tromp1 using specific anti-Tromp1 serum following immunoblot analysis with 1 x 109 protoplasmic cylinders (data not shown). Absorbed and nonabsorbed anti-OMV sera were compared for their ability to detect T.p. Ags on one-dimensional immunoblots of whole T.p. and by the TPI test as described above.
Freeze-fracture electron microscopy
Both mouse anti-OMV serum and IRS were tested for their ability to aggregate TROMPs in the outer membrane as follows: NRS (undiluted), IRS (undiluted), normal mouse serum (NMS) (diluted 1/64 in NRS), and anti-OMV serum (diluted 1/64 in NRS) were incubated with T.p., in the absence of active complement, under the conditions of the TPI test as described above. Following incubation for 16 h, the suspensions were centrifuged at 9000 x g for 10 min to pellet the treponemes. The treponemal pellets were resuspended in 0.5 ml of 2% glutaraldehyde and 0.1 M sodium cacodylate (pH 7.2) and were fixed for 1 h. Following fixation, the suspensions were centrifuged at 9000 x g for 10 min, and the treponemal pellets were resuspended in 50 µl of 20% glycerol in 0.1 M sodium cacodylate (pH 7.2). Each sample was prepared for freeze-fracture electron microscopy as described previously (5).
| Results |
|---|
|
|
|---|
To determine the specificity of the mouse anti-OMV serum,
two-dimensional immunoblots of purified T.p. outer membrane and T.p.
whole organisms were probed with the anti-OMV serum (Figs. 1
and 2).
As shown in Fig. 1
, the anti-OMV serum at a 1/1000 dilution used
against 5 x 1010 treponemal equivalents of
outer membrane detected both isomeric forms of the 31-kDa protein
Tromp1 and weakly detected the 28-kDa protein Tromp2. In addition,
several proteins at 15 kDa and 17 kDa were strongly detected as well as
a vertical migrating 34-kDa protein and a 45-kDa protein.
|
|
By comparison, a 1/1000 dilution of IRS used to probe a total extract
of T.p. from 1 x 109 organism equivalents
resulted in the detection of >40 T.p. Ag spots including the major
47-kDa lipoprotein and those comprising the endoflagellar filament
(Fig. 2
C). Again, no detection of Tromp1 or Tromp2 was
observed using IRS at this dilution. We have observed, however, that
IRS can detect Tromp1 and Tromp2 on two-dimensional immunoblots when
using 3 x 1010 T.p. equivalents of purified
outer membrane (data not shown).
Detection of Tromp1 by mouse anti-T.p. OMV serum and IRS
Because 1 x 109 T.p. organisms, which
were used above for two-dimensional analysis, only contain
1050 ng
of each TROMP, 5 µg of purified recombinant Tromp1 (12)
was used as a target Ag to further confirm the detection of Tromp1 by
the anti-OMV serum and IRS at a 1/1000 dilution. As shown in Fig. 3
, both anti-OMV serum and IRS
readily detected 5 µg of purified recombinant Tromp1, confirming the
presence of Ab against Tromp1 in the anti-OMV serum and following
experimental syphilitic infection. As also seen, the anti-OMV serum
reacted with greater intensity compared with IRS.
|
To compare the anti-OMV serum with that of IRS for
complement-dependent treponemicidal activity, the sera were tested
quantitatively by TPI. As shown in Table I
, IRS from a rabbit immune to challenge
reinfection showed high-titer treponemicidal activity, having a 100%
killing endpoint titer of 1:44 and a 50% killing endpoint titer of
1:662. This level of killing activity is consistently observed for IRS
when tested by TPI (14, 16). By comparison, the mouse
anti-OMV serum showed a strikingly higher level of treponemicidal
activity, having a 100% killing endpoint titer of 1:1,408 and a 50%
killing endpoint titer of 1:16,896; these titers were 32 and 25 times
greater, respectively, than those of IRS. The killing activity for both
IRS and the mouse anti-OMV serum was complement-dependent, because
the lowest dilutions of test samples containing heat-inactivated
complement had no treponemicidal activity. In addition, the syngeneic
mouse serum as well as NRS from a noninfected animal showed no
treponemicidal activity in the presence or absence of active
complement.
|
To determine the contribution to TPI activity in the anti-OMV
serum of the antilipoprotein Abs, these Abs were removed by
absorption with T.p. protoplasmic cylinders, devoid of outer
membrane, with exposed inner membrane-anchored lipoproteins. As shown
by immunoblot analysis (Fig. 4
),
absorption resulted in the complete removal of detectable Ab against
the 15-, 17-, 34-, and 45-kDa lipoproteins, but not against Tromp1.
When analyzed by the TPI test at the highest dilution that kills 100%
of the treponemal suspension (1:1408), the absorbed serum showed no
difference compared with the nonabsorbed serum in its ability to kill
100% of the treponemes (Table I
).
|
To determine whether the anti-OMV serum could aggregate TROMPs
when incubated with virulent T.p., as reported previously for IRS
(5), organisms were incubated under TPI conditions in the
absence of complement before freeze-fracture electron microscopy.
Organisms incubated in NRS or in a 1/64 dilution of NMS (Fig. 5
, A and C) showed
little aggregation of particles in their outer membranes. The few
aggregates detected under these conditions never exceeded two particles
per aggregate. By comparison, organisms incubated in undiluted IRS or
in a 1/64 dilution of the anti-OMV serum (Fig 5
, B and
D) showed marked aggregation of outer membrane particles. In
some cases, outer membrane particle aggregates following anti-OMV
serum incubation were observed to contain as many as seven
particles.
|
| Discussion |
|---|
|
|
|---|
Following an initial s.c. immunization and two intrasplenic boost injections, the mouse anti-OMV serum possessed complement-dependent treponemicidal activity that was found to be 32 times greater than that of IRS in its ability to kill 100% of a T.p. suspension. This is the first demonstration of an immunization in mice or rabbits that has resulted in treponemicidal activity that is significantly greater than that of infection-derived immune serum. Of particular importance was the finding by freeze-fracture analysis that anti-OMV serum incubated with T.p. caused aggregation of TROMPs in the outer membrane. Aggregation of TROMPs has heretofore only been achievable with IRS (5). This finding indicates that OMV immunization results in an Ab response against surface epitopes on these rare proteins and suggests that TROMPs are the primary targets for high-titer treponemicidal activity.
To further characterize the serum following OMV immunization,
anti-OMV serum and IRS were used for immunoblot analysis against
purified T.p. outer membrane and total T.p. proteins. In contrast to
IRS, which detected >40 T.p. proteins by two-dimensional immunoblot
analysis, anti-OMV serum at the same dilution identified only a
limited set of proteins, including Tromp1 (31 kDa), Tromp2 (28 kDa),
and Ags corresponding to lipoproteins of 15, 17, 34, and 45 kDa. We
have shown previously that the 17- and 45-kDa lipoproteins are
constituents of the outer membrane (6). The presence of Ab
against the 15- and 34-kDa lipoproteins was unexpected, because these
proteins have not been detected by either gold staining or by
immunoblot analysis in our previous outer membrane preparations
(6). The possibility that this resulted from a small
amount of inner membrane lipoprotein contamination is also unlikely
given the complete absence of Ab against the 47-kDa lipoprotein, the
most abundant inner membrane-anchored lipoprotein of T.p. (Fig. 2
A) and one that is known to be highly immunogenic in mice,
rabbits, and humans (26, 33, 34). These findings indicate
that trace amounts of the 15- and 34-kDa lipoproteins, previously
undetected in our outer membrane preparations, elicited a relatively
strong Ab response, which is consistent with the high immunogenicity of
lipoproteins (35, 36).
Immunoblot analysis of the anti-OMV serum also showed no detectable Ab against a rare 65-kDa protein that we identified previously in our outer membrane preparations (6). We have subsequently found that the presence of this protein in recent outer membrane preparations has been variable, suggesting that it may be either differentially expressed or may simply be a rare contaminant. In either case, our OMV immunization results indicate that Ab against this 65-kDa protein does not appear to be necessary for high-titer serum treponemicidal activity.
In an effort to further identify TROMPs as the targets of high-titer treponemicidal Ab, the anti-OMV serum was absorbed to remove Ab directed against both subsurface and outer membrane-associated lipoproteins. Although immunoblot analysis showed the complete removal of detectable antilipoprotein Abs from the absorbed anti-OMV serum, no loss of anti-Tromp1 Ab was observed. Furthermore, no change in the titer of this absorbed serum was observed in its ability to kill 100% of a T.p. suspension. These findings indicate that the antilipoprotein Abs do not contribute to the high-titer treponemicidal activity elicited by OMV immunization and further suggest that TROMPs are the primary targets of this activity.
Our studies suggest that Tromp1 may be an outer membrane target for bactericidal Ab. However, recent immunizations with purified recombinant Tromp1 have not resulted in significant serum killing activity. It is pertinent to note that the purified recombinant form of Tromp1 used for these immunizations does not possess properties that we have demonstrated previously for native Tromp1, including hydrophobicity, porin activity, and oligomeric conformation (10). The finding that immunization with purified OMV, presumably containing TROMPs in a native conformation, can elicit high-titer killing Ab suggests that native conformation of TROMPs may be an important factor in their ability to elicit killing Ab.
In summary, this is the first demonstration of an immunization that has resulted in high-titer complement-dependent serum treponemicidal Ab; in addition, our study suggests that outer membrane proteins are responsible for this activity. It is tempting to speculate that this level of killing Ab may contribute to protective immunity. Although the mouse model of syphilis does not show an initial skin lesion following challenge, disseminated infection involving the lymphatics, blood, spleen, and brain is well documented (31). We believe that murine immunization with purified T.p. OMV, as described in this study, provides a heretofore unavailable opportunity to address whether the outer membrane of T.p. can elicit protective immunity against challenge infection. We are hopeful that such future OMV immunization studies will provide further insight into the surface molecules responsible for the generation of protective host immunity during syphilitic infection.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 An equal contribution to this study was made by D.R.B. and C.I.C., who should be considered co-first authors of this work. ![]()
3 Address correspondence and reprint requests to Dr. David R. Blanco, Department of Microbiology, Immunology, and Molecular Genetics, Center for Health Sciences 43-239, University of California School of Medicine, Los Angeles, CA 90095-1747. E-mail address: ![]()
4 Abbreviations used in this paper: T.p., Treponema pallidum; TROMP, T.p. rare outer membrane protein; OMV, outer membrane vesicles; IRS, immune rabbit serum; TPI, T.p. immobilization; NRS, normal rabbit serum; NMS, normal mouse serum. ![]()
Received for publication February 11, 1999. Accepted for publication June 11, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. R. Blanco, C. I. Champion, A. Dooley, D. L. Cox, J. P. Whitelegge, K. Faull, and M. A. Lovett A Monoclonal Antibody That Conveys In Vitro Killing and Partial Protection in Experimental Syphilis Binds a Phosphorylcholine Surface Epitope of Treponema pallidum Infect. Immun., May 1, 2005; 73(5): 3083 - 3095. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. McKevitt, K. Patel, D. Smajs, M. Marsh, M. McLoughlin, S. J. Norris, G. M. Weinstock, and T. Palzkill Systematic Cloning of Treponema pallidum Open Reading Frames for Protein Expression and Antigen Discovery Genome Res., July 1, 2003; 13(7): 1665 - 1674. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Shang, C. I. Champion, X.-Y. Wu, J. T. Skare, D. R. Blanco, J. N. Miller, and M. A. Lovett Comparison of Protection in Rabbits against Host-Adapted and Cultivated Borrelia burgdorferi following Infection-Derived Immunity or Immunization with Outer Membrane Vesicles or Outer Surface Protein A Infect. Immun., July 1, 2000; 68(7): 4189 - 4199. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Centurion-Lara, C. Godornes, C. Castro, W. C. Van Voorhis, and S. A. Lukehart The tprK Gene Is Heterogeneous among Treponema pallidum Strains and Has Multiple Alleles Infect. Immun., February 1, 2000; 68(2): 824 - 831. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |